A scoping review of interventions to prevent and treat adverse events during treatment of rifampin-susceptible tuberculosis

There has been considerable research on improving the safety and tolerability of tuberculosis treatment, but its impact is limited by under-powered studies, the lack of inclusion of key subgroups, and important gaps in the research portfolio (uncertainties about the safety of pyrazinamide and the efficacy of hepatoprotectants, lack of research on ways to manage and prevent treatment-related nausea). It is concerning that the research pipeline for interventions to improve safety and tolerability appears to be quite limited Our review has identified promising interventions that may make treatment better tolerated, and hence, more effective.